Tiotropium: An inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease

Pharmacotherapy

Volumn 23, Issue 2, 2003, Pages 183-189

  Panning, Chad A ^a,b   DeBisschop, Mike ^a  

^a UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

^b Univ WY Fam Pract Residency Prog   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; METHACHOLINE; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ANTICHOLINERGIC EFFECT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HUMAN; METERED DOSE INHALER; POWDER INHALER; SHORT SURVEY; SPIROMETRY; TREATMENT OUTCOME; XEROSTOMIA;

ADMINISTRATION, INHALATION; CHOLINERGIC ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; SCOPOLAMINE DERIVATIVES;

EID: 0037318622     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.2.183.32082     Document Type: Short Survey

References (23)

1. Snow V, Lascher S, Mottur-Pilson C, for the Joint Expert Panel on COPD. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001;134:595-9.
2. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80.
3. Pauwels R, Anthonisen N, Bailey WC, et al. Executive summary of global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute-World Health Organization (NHLBI-WHO) workshop report 2001. Available from http://www.goldcopd.com/docs.html. Accessed September 9, 2002.
4. Barnes PJ, Belvisi MG, Mak JCW, Haddad EB, O'Connor B. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airway disease. Life Sci 1995;56:853-9.
5. Joos GF. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch Chest Dis 2000;55:411-14.
6. Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:S72-9.
7. Lefkowitz RJ, Hoffman BB, Taylor P. Neurohumoral transmission: the autonomic and somatic motor nervous systems. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. Elmsford, NY: Pergamon Press, Inc., 1990;84-121.
8. 3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994;45:899-907.
9. Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R. Tiotropium: mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64:457-64.
10. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996;154:876-80.
11. Disse B, Raichl R, Speck GA, Travnecker W, Rominger KL, Hammer R. BA679BR, a novel anticholinergic bronchodilator. Life Sci 1993;52:537-44.
12. Witek TJ. The fate of inhaled drugs: the pharmacokinetics and pharmacodynamics of drugs administered by aerosol. Respir Care 2000;45:826-30.
13. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117:S63-6.
14. Takahashi T, Belvisi MG, Patel H, et al. Effect of tiotropium bromide, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea-pig and human airways. Am J Respir Crit Care Med 1994;150:1640-5.
15. Maesen FPV, Smeets JJ, Sledsen TJH, Wald FDM, Cornelissen PJG, on behalf of the Dutch Study Group. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease. Eur Respir J 1995;8:1506-13.
16. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136-42.
17. Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr, for the U.S. Tiotropium Study Group. The spirometric efficacy of once daily dosing with tiotropium in stable COPD. Chest 2000;118:1294-302.
18. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
19. Jones PW, Quirk FH, Beveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation. Am Rev Respir Dis 1992;145:1321-7.
20. van Noord JA, Bantje ThA, Eland ME, Korducki L, Cornelissen PJG. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000;55:289-94.
21. Vincken W, van NoordJA, Greefhorst APM, et al, on behalf of the Dutch-Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
22. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
23. Calverley PM. The future for tiotropium. Chest 2000; 117:S67-9.